T0	Interventions 14 32	placebo-controlled
T1	Interventions 50 74	ganitumab or conatumumab
T2	Interventions 278 289	bevacizumab
T3	Interventions 294 306	aflibercept.
T4	Interventions 347 358	conatumumab
T5	Interventions 429 438	ganitumab
T6	Interventions 734 786	fluoropyrimidine- and oxaliplatin-based chemotherapy
T7	Interventions 824 917	intravenous FOLFIRI plus conatumumab 10 mg/kg (Arm A), ganitumab 12 mg/kg (Arm B), or placebo
T8	Interventions 1451 1474	CONCLUSIONS Conatumumab
T9	Interventions 1480 1507	not ganitumab, plus FOLFIRI